Thermo Fisher Scientific

Thermo Fisher Scientific announced that it expanded its bioprocessing capabilities across Asia. The Waltham, Massachusetts-based company says the expansion reinforces its commitment to supporting the region’s growing biopharmaceutical industry. It plans to introduce a new Bioprocess Design Center in Hyderabad, India, in addition to expansions in existing Bioprocess Design Centers in Incheon, Korea, and Singapore.…

Thermo Fisher Scientific (NYSE:TMO) announced that it completed its acquisition of a Sanofi facility in New Jersey. The company acquired Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey. In July, the company announced its plans to acquire this site and continue producing a portfolio of Sanofi therapies there while opening the facility…

Thermo Fisher Scientific recently announced plans to acquire Sanofi’s sterile manufacturing site in Ridgefield, New Jersey, and continue producing a portfolio of Sanofi therapies there while opening the facility to additional pharmaceutical and biotech customers. The plant performs sterile fill-finish and packaging, and has more than 200 employees, all of whom will join Thermo Fisher…

Thermo Fisher Scientific announced today that it plans to invest an additional $2 billion in the U.S. over the next four years. The company said its investment should strengthen American innovation, manufacturing and economic competitiveness in the life sciences sector. It also comes as a number of companies consider investing in U.S. infrastructure amid potential…

Thermo Fisher Scientific announced today that it introduced more sustainable packaging for 125,000 Invitrogen antibodies. The Waltham, Massachusetts-based company said the transition from cold-chain packaging to ambient temperature shipping from distribution center to customer reduces package material mass and improves the customer experience. This comes as part of the company’s global sustainability efforts. According to…

Thermo Fisher Scientific has expanded its clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new $58 million investment adds 72,500 sq ft. to the company’s footprint and increases the site’s chemistry, manufacturing, and control analytical capabilities for biopharmaceutical therapy development. “As research in biopharmaceutical therapies continues to rapidly…

Thermo Fisher Scientific announced that it opened a new clinical and commercial ultra-cold facility in the Netherlands. The company aims to expand its clinical trial network in Europe and accelerate the development of advanced therapies. Its new current good manufacturing practice (cGMP) facility in Bleiswijk offers pharmaceutical and biopharma customers tailored, end-to-end support throughout the…

Thermo Fisher Scientific posted third-quarter results today that beat the consensus forecast on Wall Street. The company reported profits of $1.5 billion, or $3.79 per share, on sales of $10.7 billion for the three months ended Sept. 30, for a bottom-line loss of 21.3% on sales growth of 14.4% compared with Q3 2021. Adjusted to…

Thermo Fisher Scientific (NYSE:TMO) announced today that it unveiled the Gibco CTS DynaCellect magnetic separation system. Waltham, Massachusetts-based Thermo Fisher designed DynaCellect to help cell therapy developers easily move from process and clinical development to commercial manufacturing. The next-generation instrument features cell isolation, activation and depletion along with Dynabeads magnetic beads removal. Thermo Fisher said…

COVID-19 vaccine development and rollout were crucial to gaining control of the pandemic. When the success of these efforts became dependent on the ability to maintain lower than typical temperatures during distribution, the importance of reliable and continuous cold chain solutions for mRNA-based formulations was thrust into the spotlight. Beyond pandemic mitigation measures and outside…